新股消息 | 微创医疗机器人递表港交所主板，图迈等旗舰产品或接近注册批准阶段

智通财经2021-06-10

智通财经APP获悉，据港交所6月10日披露，上海微创医疗机器人(集团)股份有限公司向港交所主板提交上市申请，摩根大通及中金公司为联席保荐人。该公司是全球第一梯队的手术机器人公司。据弗若斯特沙利文的资料，中国每年进行的机器人辅助腔镜手术数量由2015年的11,445例增加至2020年的47,379例，扩张3.1倍，并预期自2020年进一步增加至2026年的681,098例，扩张13.4倍，2020年...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

1啦
2021-06-13
1啦
观望呗
Bluez
2021-06-11
Bluez
是这样吗
- Bluez:
  是吗
Bluez
2021-06-11
Bluez
是吗$MAPLETREE COMMERCIAL TRUST(N2IU.SI)$

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2142221023?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/f1244793084c6388467f46fc7c39784b","is_english":false,"pubTime":"2021-06-10 22:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2142221023","market":"hk","top_or_hot":-1,"title":"新股消息 | 微创医疗机器人递表港交所主板，图迈等旗舰产品或接近注册批准阶段","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，据港交所6月10日披露，上海微创医疗机器人(集团)股份有限公司向港交所主板提交上市申请，摩根大通及中金公司为联席保荐人。该公司是全球第一梯队的手术机器人公司。据弗若斯特沙利文的资料，中国每年进行的机器人辅助腔镜手术数量由2015年的11,445例增加至2020年的47,379例，扩张3.1倍，并预期自2020年进一步增加至2026年的681,098例，扩张13.4倍，2020年...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/492550.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新股消息 | 微创医疗机器人递表港交所主板，图迈等旗舰产品或接近注册批准阶段</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新股消息 | 微创医疗机器人递表港交所主板，图迈等旗舰产品或接近注册批准阶段\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-10 22:30 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/492550.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，据港交所6月10日披露，上海微创医疗机器人(集团)股份有限公司向港交所主板提交上市申请，摩根大通及中金公司为联席保荐人。该公司是全球第一梯队的手术机器人公司。据弗若斯特沙利文的资料，中国每年进行的机器人辅助腔镜手术数量由2015年的11,445例增加至2020年的47,379例，扩张3.1倍，并预期自2020年进一步增加至2026年的681,098例，扩张13.4倍，2020年...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/492550.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300024","symbol_name":"机器人","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/492550.html","article_id":"2142221023","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/f1244793084c6388467f46fc7c39784b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2142221023","pubTimestamp":1623335400,"columns":[{"name":"新股","id":7,"label_key":null},{"name":"递表消息","id":18,"label_key":null}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，据港交所6月10日披露，上海微创医疗机器人(集团)股份有限公司向港交所主板提交上市申请，摩根大通及中金公司为联席保荐人。公司旗舰产品，即图迈腔镜手术机器人、蜻蜓眼三维电子腹腔内窥镜及鸿鹄骨科手术机器人，均已被纳入国家药监局创新医疗器械特别审查程序。图迈及鸿鹄处于或接近注册批准阶段，而蜻蜓眼已于最近获得国家药监局批准。财务方面，公司于往绩记录期间的各个期间均产生经营亏损。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300024":"机器人","00853":"微创医疗"},"translate_title":"New shares news minimally invasive medical robots are handed over to flagship products such as the main board of the Hong Kong Stock Exchange and Tumai or close to the registration approval stage","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300024":1,"00853":1},"content_text":"智通财经APP获悉，据港交所6月10日披露，上海微创医疗机器人(集团)股份有限公司向港交所主板提交上市申请，摩根大通及中金公司为联席保荐人。该公司是全球第一梯队的手术机器人公司。据弗若斯特沙利文的资料，中国每年进行的机器人辅助腔镜手术数量由2015年的11,445例增加至2020年的47,379例，扩张3.1倍，并预期自2020年进一步增加至2026年的681,098例，扩张13.4倍，2020年及2026年的渗透率分别约为0.5%及3.0%。根据同一份资料，该公司是全球行业中唯一一家拥有覆盖五大主要和快速增长的手术专科(即腔镜、骨科、泛血管、经自然腔道及经皮穿刺手术)产品组合的公司。公司旗舰产品，即图迈®腔镜手术机器人、蜻蜓眼®三维电子腹腔内窥镜及鸿鹄®骨科手术机器人，均已被纳入国家药监局创新医疗器械特别审查程序。图迈及鸿鹄处于或接近注册批准阶段，而蜻蜓眼已于最近获得国家药监局批准。财务方面，公司于往绩记录期间的各个期间均产生经营亏损。截至2019年及2020年12月31日止年度以及截至2021年3月31日止三个月，分别录得亏损净额人民币(下同)6980万元、2.093亿元及1.148亿元，主要是由于公司的研发成本及行政开支所致。于2019年、2020年及截至2021年3月31日止三个月，公司研发成本分别为6190万元、1.354亿元及9010万元。公司预期，研发成本将随着未来在研产品的研发活动增加而增加。此外，公司净资产由2019年12月31日的2641万元大幅上升至2020年12月31日的14.415亿元，主要由于公司在2020年获得约15亿元的注资。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":182812960,"gmtCreate":1623562245750,"gmtModify":1634031640840,"author":{"id":"3581894098069462","authorId":"3581894098069462","name":"1啦","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581894098069462","authorIdStr":"3581894098069462"},"htmlText":"观望呗","listText":"观望呗","text":"观望呗","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/182812960","repostId":2142221023,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":183770965,"gmtCreate":1623364294657,"gmtModify":1634034278219,"author":{"id":"3585481693131980","authorId":"3585481693131980","name":"Bluez","avatar":"https://static.tigerbbs.com/e319262691b62ffc43be5e2d506ecdc7","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3585481693131980","authorIdStr":"3585481693131980"},"htmlText":"是这样吗","listText":"是这样吗","text":"是这样吗","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/183770965","repostId":2142221023,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4672546,"gmtCreate":1623364474232,"gmtModify":1635328891158,"authorId":3585481693131980,"author":{"id":3585481693131980,"idStr":"3585481693131980","authorId":3585481693131980,"name":"Bluez","avatar":"https://static.tigerbbs.com/e319262691b62ffc43be5e2d506ecdc7","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183770965,"type":1,"supId":0,"prevId":0,"content":"是吗","text":"是吗","html":"是吗"}],"langContent":"CN"},{"id":183747837,"gmtCreate":1623364257329,"gmtModify":1631888414965,"author":{"id":"3585481693131980","authorId":"3585481693131980","name":"Bluez","avatar":"https://static.tigerbbs.com/e319262691b62ffc43be5e2d506ecdc7","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3585481693131980","authorIdStr":"3585481693131980"},"htmlText":"是吗<a href=\"https://laohu8.com/S/N2IU.SI\">$MAPLETREE COMMERCIAL TRUST(N2IU.SI)$</a>","listText":"是吗<a href=\"https://laohu8.com/S/N2IU.SI\">$MAPLETREE COMMERCIAL TRUST(N2IU.SI)$</a>","text":"是吗$MAPLETREE COMMERCIAL TRUST(N2IU.SI)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/183747837","repostId":2142221023,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":5,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2142221023"}